Sionna Insider: 10,250-Share Option Exercise and Sale via 10b5-1 Plan
Rhea-AI Filing Summary
Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, reported transactions on 09/04/2025 under a Rule 10b5-1 plan. She exercised a non-qualified stock option to purchase 10,250 shares at an exercise price of $6.11 per share and immediately sold 10,250 common shares at a weighted-average price of $23.12, with individual sale prices ranging from $21.80 to $24.52. Following these transactions, she reports 0 shares beneficially owned. The option vests 25% on June 3, 2025, with the remainder vesting monthly over 36 months.
Positive
- Exercise and sale executed under a Rule 10b5-1 plan, indicating trades were preplanned (plan adopted June 5, 2025).
- Full disclosure of weighted-average sale price range ($21.80 to $24.52) and willingness to provide per-trade details upon request.
Negative
- Reported beneficial ownership reduced to 0 shares after the sales, which may be notable given the reporting person’s officer status.
- Immediate sale of all exercised shares removes insider share ownership disclosed in this filing.
Insights
TL;DR Insider exercised options at $6.11 and sold the resulting 10,250 shares via a 10b5-1 plan at a ~$23.12 average, leaving no reported holdings.
The transaction is a routine, preplanned insider sale executed under a Rule 10b5-1 arrangement, which provides regulatory safe harbor for trading while in possession of material nonpublic information. The exercise captured intrinsic value between the $6.11 strike and the reported sale prices, realizing a substantial gross spread per share. Because the reporting person is an officer and the sale reduced reported beneficial ownership to zero, investors may note the change in insider exposure but the filing itself does not provide information about reasons for the sale or company fundamentals.
TL;DR Transaction follows a documented 10b5-1 plan; disclosure and price ranges are provided—no indications of governance breaches in the filing.
The filing discloses the adoption date of the 10b5-1 plan (June 5, 2025) and price ranges for the executed sales, enhancing transparency. Vesting schedule details for the option are included, clarifying the option economics and remaining vesting cadence. From a governance perspective, the use of a pre-established trading plan and the explicit offer to provide granular sale-level data on request align with standard disclosure practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | -- |
| Exercise | Common Stock | 10,250 | $6.11 | $63K |
| Sale | Common Stock | 10,250 | $23.12 | $237K |
Footnotes (1)
- This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.80 to $24.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any sercurityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. 25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
